We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

103 hedge funds and large institutions have $73.1M invested in Sanofi Contingent Value Rights in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

3% less funds holding

Funds holding: 106 → 103 (-3)

9% less capital invested

Capital invested by funds: $80.4M → $73.1M (-$7.35M)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

39% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 18

Holders
103
Holders Change
-3
Holders Change %
-2.83%
% of All Funds
2.3%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
8
Increased
11
Reduced
18
Closed
11
Calls
$15.1M
Puts
–
Net Calls
+$15.1M
Net Calls Change
+$15.1M

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonehill Capital Management
New York
+$2.73M
2
HCM
Highbridge Capital Management
New York
+$295K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$65.3K
4
Goldman Sachs
Goldman Sachs
New York
+$45.5K
5
TSS
Two Sigma Securities
New York
+$15.1K

Top Sellers

Rank Fund Capital Flow
1
BMO
Beck Mack & Oliver
New York
-$174K
2
CI
Cowen Inc
New York
-$30K
3
Citadel Advisors
Citadel Advisors
Florida
-$23.1K
4
MCM
Mainstay Capital Management
Michigan
-$14K
5
CS
Credit Suisse
Switzerland
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$35K +$2.31K +4,659 +7%
AL
27
Arnhold LLC
New York
$31K – – –
GI
28
GAMCO Investors
Connecticut
$30K – – –
Korea Investment Corp
29
Korea Investment Corp
South Korea
$23K – – –
Royal London Asset Management
30
Royal London Asset Management
United Kingdom
$21K – – –
ZIG
31
Zuckerman Investment Group
Illinois
$20K – – –
Ameriprise
32
Ameriprise
Minnesota
$16K -$354 -712 -2%
Morgan Stanley
33
Morgan Stanley
New York
$15K -$323 -651 -2%
TSS
34
Two Sigma Securities
New York
$15K +$15.1K +30,368 New
SDWMA
35
Schneider Downs Wealth Management Advisors
Pennsylvania
$12K – – –
WVP
36
Worth Venture Partners
New Jersey
$12K +$11 +22 +0.1%
Commonwealth Equity Services
37
Commonwealth Equity Services
Massachusetts
$10K -$23 -46 -0.2%
CHAM
38
Clear Harbor Asset Management
Connecticut
$8K -$8.94K -18,000 -54%
LPL Financial
39
LPL Financial
California
$8K -$5 -10 -0.1%
MC
40
Moors & Cabot
Massachusetts
$8K – – –
WEC
41
Winslow Evans & Crocker
Massachusetts
$8K – – –
Citadel Advisors
42
Citadel Advisors
Florida
$7K -$23.1K -46,593 -77%
FHA
43
Flagship Harbor Advisors
Massachusetts
$7K – – –
HK
44
Horizon Kinetics
New York
$7K – – –
RWP
45
RWA Wealth Partners
Massachusetts
$7K – – –
William Blair & Company
46
William Blair & Company
Illinois
$7K – – –
Bank of America
47
Bank of America
North Carolina
$6K -$792 -1,595 -11%
BIA
48
Biondo Investment Advisors
Pennsylvania
$6K -$596 -1,200 -9%
EAM
49
Erste Asset Management
Austria
$5.64K +$5.96K +12,000 New
US Bancorp
50
US Bancorp
Minnesota
$5K -$158 -318 -3%
1
2
3 4

GCVRZ Hedge Fund Activity: Q4 2018 in Review

103 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2018, worth a combined $73.1M — down 9.1% from $80.4M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of GCVRZ and 8 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 11 added.

The largest buyer was Stonehill Capital Management, adding an estimated $2.73M. The largest seller was Beck Mack & Oliver, exiting entirely with an estimated $174K sold.

  • 103 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2018, down from 106 in Q3 2018.
  • Funds reported $73.1M of Sanofi Contingent Value Rights stock for Q4 2018, down 9.1% quarter-over-quarter.
  • 8 funds opened new Sanofi Contingent Value Rights positions in Q4 2018 and 11 closed out, a net change of -3 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q4 2018 was Stonehill Capital Management, an estimated $2.73M added.
  • The largest Sanofi Contingent Value Rights seller in Q4 2018 was Beck Mack & Oliver, an estimated $174K sold.

Based on aggregated 13F filings for Q4 2018.